Ribopeutic is a China-based RNA therapeutics developer that combines artificial intelligence with laboratory validation to identify RNA structures targetable by small molecules. Founded in 2022 and emerging from stealth, the company is advancing its pipeline toward investigational new drug (IND) filings. Its programs target central nervous system disorders, cancer, and autoimmune conditions. Ribopeutic recently secured close to 100 million yuan (~$13.9M) in pre-A financing to push its lead programs forward. The funding is intended to support advancement of lead programs and to expand the company’s early-stage pipeline.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2025